Twist Bioscience Corp
TWST
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.4B
Close$
$10.15
94.5% downside
Current Fair Value
94.5% downsideOvervalued by 94.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.40 Billion |
|---|---|
| Enterprise Value | $10.38 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.3 |
| Beta | 2.22 |
| Outstanding Shares | 62,403,000 |
Return
| Return on Equity | -30.67% |
|---|---|
| Return on Assets | -20.33% |
| Return on Invested Capital | -25.50% |
Valuation & Multiples
| P/E Ratio | -75.22 |
|---|---|
| PEG | 27.66 |
| Price to Sales | 30.5 |
| Price to Book Ratio | 26.15 |
| Enterprise Value to Revenue | 24.04 |
| Enterprise Value to EBIT | -73.74 |
| Enterprise Value to Net Income | -76 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.22 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 3, 2026
EPS Estimate
$-0.51
Average shareholder expectationRevenue Estimate
$114.55 M
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-0.44
Average shareholder expectationRevenue Estimate
$123.57 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3914▼ 12.50% |
|---|---|
| Total Calls | 364,600▲ 64.01% |
| Total Puts | 142,700▲ 24.30% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 123.33%▼ 1.50% |
|---|---|
| Total Invested | $7.91B▲ 116.28% |
| Investors Holding | 348▲ 61.00% |
ESG Score
No data
About Twist Bioscience Corp
CEO: Emily Leproust Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary techno...